Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors Mukul PrasadSashigala PonnalaguHerbert Schwarz Original Article 17 March 2022 Pages: 2583 - 2596
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study Chao JingJunyun WangWei Deng Original Article 18 March 2022 Pages: 2597 - 2608
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors E. Gefard-GontierR. MarkichM. Kostine Original Article 19 March 2022 Pages: 2609 - 2618
Altered immunity to microbiota, B cell activation and depleted γδ/resident memory T cells in colorectal cancer Alistair NobleEdward T. PringStella C. Knight Original Article Open access 22 March 2022 Pages: 2619 - 2629
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma Chi-Jung WuPei-Chang LeeYi-Hsiang Huang Original Article Open access 28 March 2022 Pages: 2631 - 2643
The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma Yusuke ShinchiShiho IshizukaMakoto Suzuki Original Article 29 March 2022 Pages: 2645 - 2661
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy Yonggui TianChunli WenYi Zhang Original Article 29 March 2022 Pages: 2663 - 2675
OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression Shuai YangJiangang ZhangYongsheng Li Original Article 30 March 2022 Pages: 2677 - 2689
Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models Karolina ŽilionytėUgnė BagdzevičiūtėVita Pašukonienė Original Article 01 April 2022 Pages: 2691 - 2700
Correction to: Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models Karolina ŽilionytėUgnė BagdzevičiūtėVita Pašukonienė Correction 25 April 2022 Pages: 2701 - 2701
Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma Yoshitaka NaritaYoshiko OkitaYoshiki Arakawa Original Article Open access 04 April 2022 Pages: 2703 - 2715
Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions Ming WangZhongyu QinZhihai Qin Original Article 15 April 2022 Pages: 2717 - 2730
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma Marie-Léa GauciJérôme GiustinianiAnne Marie-Cardine Original Article Open access 15 April 2022 Pages: 2731 - 2742
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy Yasuhiro NagataShinichi KageyamaHiroshi Shiku Original Article 16 April 2022 Pages: 2743 - 2755
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study Kohei FujitaPaul ElkingtonTadashi Mio Original Article 16 April 2022 Pages: 2757 - 2764
Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer Akinao KanetaShotaro NakajimaKoji Kono Original Article 16 April 2022 Pages: 2765 - 2776
Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors Myeong Joon KimKyeong Hee HongSang-Jun Ha Original Article 18 April 2022 Pages: 2777 - 2789
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab Jamila TalbPaul Takam KamgaEtienne Giroux Leprieur Original Article 18 April 2022 Pages: 2791 - 2799
Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor Yuedi WangYiyuan GaoYiwei Chu Original Article 19 April 2022 Pages: 2801 - 2814
Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis Takashi YoshidaChisato OheOn behalf of the Japan Urological Oncology Group Original Article 20 April 2022 Pages: 2815 - 2828
Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy Jung Hyun HerDominik PretscherJan Endell Research Report Open access 29 March 2022 Pages: 2829 - 2836